SLC7A11-AS1: A Potential Drug Target and Biomarker (G641364)

Target Name: SLC7A11-AS1

NCBI ID: G641364

SLC7A11-AS1

Other Name(s): SLC7A11 antisense RNA 1

SLC7A11-AS1: A Potential Drug Target and Biomarker

Sodium channels play a crucial role in the regulation of various physiological processes in the body, including muscle and nerve function, as well as the contraction and relaxation of blood vessels. The SLC7A11 gene, which encodes a sodium channel protein, has been implicated in numerous physiological processes, including neuronal excitability and cardiovascular function. In addition, SLC7A11 has also been implicated in the development and progression of various neurological and psychiatric disorders.

The SLC7A11 gene has four splice variants, SLC7A11-AS1, SLC7A11-AS2, SLC7A11-AS3, and SLC7A11-AS4. SLC7A11-AS1 is a splicing variant that has been shown to encode a protein with distinct molecular and functional properties compared to the other splice variants. SLC7A11-AS1 has a calculated molecular mass of 123.13 kDa and contains 11 open reading frames (ORFs) with an average length of 33.4 amino acids per ORF.

SLC7A11-AS1 has been shown to play a crucial role in the regulation of neuronal excitability and synaptic plasticity. SLC7A11-AS1 has been shown to be involved in the regulation of neurotransmitter release from axons in the central nervous system (CNS), including dopamine and serotonin. SLC7A11-AS1 has also been shown to play a role in the regulation of muscle contraction and relaxation, as well as the regulation of blood vessel diameter.

In addition to its role in neurotransmitter regulation, SLC7A11-AS1 has also been shown to be involved in the development and progression of various psychiatric and neurological disorders. SLC7A11 has been implicated in the development of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. In addition, SLC7A11 has also been implicated in the development of various psychiatric disorders, including depression and anxiety.

The SLC7A11 gene has also been the focus of research efforts aimed at developing new therapeutic approaches for a variety of psychiatric and neurological disorders. SLC7A11 has been shown to be a potential drug target, with several studies suggesting that inhibition of SLC7A11 function may be a promising approach for the treatment of various psychiatric and neurological disorders. In addition, SLC7A11 has also been shown to be a potential biomarker for the diagnosis and progression of certain psychiatric and neurological disorders.

One approach to inhibiting SLC7A11 function is through the use of small molecule inhibitors. These inhibitors can be designed to specifically bind to SLC7A11 and prevent it from functioning. One such inhibitor is a peptide that contains the amino acid Asp-212. Asp-212 is a critical residue in the SLC7A11 protein and is involved in its function. By binding to Asp-212, this inhibitor can prevent SLC7A11 from functioning and may be a useful approach for the treatment of psychiatric and neurological disorders.

Another approach to inhibiting SLC7A11 function is through the use of RNA interference (RNAi) technology. RNAi is a technique that can be used to knockdown (reduce the amount of) a specific gene in the genome. By using RNAi to knockdown SLC7A11 expression, researchers can study its function and determine if it is involved in the development or progression of various psychiatric and neurological disorders. One possible approach to using RNAi

Protein Name: SLC7A11 Antisense RNA 1

The "SLC7A11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A11-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets